Simcere Pharmaceutical Group
http://en.simcere.com/
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Simcere Pharmaceutical Group
AZ, Junshi Part Ways Amid China IO Commercial Struggle
Multinationals including AstraZeneca are retreating from China’s overcrowded immuno-oncology market but one exception - Pfizer - remains steadfast.
Asia Deal Watch: Cytokinetics Licenses China Rights For Omecamtiv To Ji Xing
Plus deals involving Sun's SPARC/Visiox, Twist/Sosei, BeiGene, Leads Biolabs, Qilu/Arbutus, Hansoh/Keros, Simcere/Avilex and Cytokinetics/Ji Xing.
3D Med, Alphamab Get First SubQ Immuno-Oncology Approval, In China
A landmark approval and domestic tie-up in China mark the fast innovation that is shaping the country’s health sector.
Tech Transfer Roundup: Athenex, PDS Align With National Cancer Institute On Oncology R&D
Athenex expands its portfolio of T-cell receptor therapy technology under NCI license agreement; PDS Biotechnology accesses institute’s TARP tumor antigen technology.
Company Information
- Industry
-
Pharmaceuticals
- Generic Drugs
- OTC, Consumer
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Other Names / Subsidiaries
-
- Jilin Boda Pharmaceutical Co., Ltd.
- ChinaVax
- Master Luck Corporation Limited
- Jiangsu Simcere Pharmaceutical R&D Co., Ltd.
- Jiangsu Yanshen Biological Technology Stock Co., Ltd.
- Nanjing Tung Chit Pharmaceutical Co., Ltd.
- Shandong Simcere Medgenn Bio-Pharmaceutical Co. Ltd.
- Wuhu Zhong Ren Pharmaceutical Co. Ltd.
- Xiangao Investment Company Ltd.
- Yantai Medgenn Co. Ltd.
- Jiangsu Simcere Pharmaceutical Co., Ltd.